慢性肾脏病患者接种新型冠状病毒疫苗有效力及接种策略的研究进展  

Research progress on the efficacy and strategy of SARS-CoV-2 vaccination in patients with chronic kidney disease

作　　者：张今宜 李月红 Jinyi Zhang;Yuehong Li(Tsinghua University School of Medicine,Beijing 102218,China;Department of Nephrology,Beijing Tsinghua Changgeng Hospital,Beijing 102218,China)

机构地区：[1]清华大学医学院,北京102218 [2]北京清华长庚医院肾内科,102218

出　　处：《中华肾病研究电子杂志》2024年第2期97-100,共4页Chinese Journal of Kidney Disease Investigation（Electronic Edition）

基　　金：首都临床特色应用研究(Z181100001718129);北京市医院管理中心临床医学发展专项经费(YGLX202332)。

摘　　要：慢性肾脏病尤其是终末期肾病接受肾脏替代治疗的患者,在新型冠状病毒感染疫情中面临巨大风险。研究显示,慢性肾脏病患者接种现有的新冠疫苗安全性较高,且全程接种能使大多数慢性肾脏病患者产生特异性抗体。但疫苗在慢性肾脏病患者中产生的体液反应和效力均显著弱于健康人群。增加疫苗接种剂次和采用混合接种对提高疫苗在慢性肾脏病患者中的保护效力具有潜在价值,但相关的接种策略仍值得进一步研究。本文综述了慢性肾脏病患者接种新冠疫苗的可行性、安全性、有效力及针对性接种策略方面的研究进展。Patients with chronic kidney disease, especially end-stage renal disease, who are receiving renal replacement therapy, are at great risk in the epidemic of COVID-19. Studies have shown that the existing COVID-19 vaccines are safe for patients with chronic kidney disease, and the whole course of vaccination can produce specific antibodies in most patients with chronic kidney disease. However, the humoral response and efficacy of the vaccines in patients with chronic kidney disease were significantly weaker than in healthy people. Increase of the number of vaccinations and use of combined vaccinations may have potential value in improving the protective efficacy of the vaccines in patients with chronic kidney disease, but the relevant vaccination strategies still need to be further studied. This paper reviewed the research progress on the feasibility, safety, efficacy, and targeted vaccination strategies of the SARS-CoV-2 vaccination for patients with chronic kidney disease.

关 键 词：慢性肾脏疾病 终末期肾病 透析 新型冠状病毒 疫苗接种 

分 类 号：R692[医药卫生—泌尿科学]